Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus

In Vivo. 2022 May-Jun;36(3):1491-1496. doi: 10.21873/invivo.12856.

Abstract

Background/aim: Recent advances in antiviral treatment have achieved a sustained viral response (SVR) in over 95% of hepatitis C virus (HCV) infections. HCV elimination is suggested to improve several lifestyle-related factors; however, few studies have focused on dietary habit-/appetite-related factors.

Patients and methods: HCV-infected patients who received Daclatasvir/Asnaprevir (DCV/ASV) therapy were enrolled, and the changes in appetite-related molecules after antiviral therapy were assessed with a multiple cytokine-measuring system.

Results: Among 119 HCV-infected patients who received DCV/ASV treatment, 104 (87.3%) achieved an SVR. In the SVR group, DCV/ASV treatment improved several liver-related variables at 24 weeks after the completion of therapy. In patients with an SVR, the values of glucagon-like peptide 1 (GLP-1) and leptin were significantly increased at 24 weeks after completing direct-acting antiviral therapy. However, no significant change was observed in non-SVR patients, regardless of the receipt of direct-acting antiviral treatment.

Conclusion: Gastrointestinal hormones related to the dietary habit and/or appetite may be influenced by HCV elimination.

Keywords: Chronic hepatitis C; appetite-related hormones; direct acting antiviral; sustained viral response.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Appetite
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Isoquinolines / therapeutic use
  • Sulfonamides

Substances

  • Antiviral Agents
  • Isoquinolines
  • Sulfonamides